SYRE Company Profile and Key Details

NASDAQ : SYRE

Spyre Therapeutics

$69.13

-0.29-0.42%

At Close 4:00 PM

69.16

ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Spyre Therapeutics, Inc. (SYRE) stock declined over -0.42%, trading at $69.13 on NASDAQ, down from the previous close of $69.42. The stock opened at $68.26, fluctuating between $67.18 and $71.67 in the recent session.

Stock Snapshot

69.42

Prev. Close

4.18B

Market Cap

67.18

Day Low

-34.91

P/E Ratio

-1.98

EPS (TTM)

N/A

Cash Flow per Share

68.26

Open

60.4M

Number of Shares

71.67

Day High

77.38%

Free Float in %

N/A

Book Value

991.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	68.26	71.67	67.18	69.13	991.59K
Apr 30, 2026	72.33	75.00	72.08	74.45	994.56K
Apr 29, 2026	68.25	73.61	67.50	71.89	1.76M
Apr 28, 2026	72.10	73.96	68.20	68.63	1.03M
Apr 27, 2026	69.53	72.30	69.53	71.90	658.37K
Apr 23, 2026	73.01	73.73	68.33	69.24	659.91K
Apr 22, 2026	72.96	74.35	71.71	73.00	1.03M
Apr 21, 2026	73.39	74.84	69.95	71.27	1.29M
Apr 20, 2026	72.20	74.68	72.03	73.39	881.64K
Apr 17, 2026	70.32	74.60	70.21	73.01	2.11M
Apr 16, 2026	68.94	70.30	66.88	69.70	2.19M
Apr 14, 2026	67.68	67.68	60.75	64.01	1.67M
Apr 13, 2026	67.00	75.00	59.02	63.27	5.34M
Apr 10, 2026	51.40	52.98	50.85	51.29	498.65K
Apr 09, 2026	51.63	52.77	51.20	51.77	585.1K
Apr 08, 2026	52.70	54.39	50.39	51.98	1.04M
Apr 07, 2026	48.97	51.26	48.83	51.20	799.3K
Apr 06, 2026	47.58	49.85	46.79	48.98	791.68K
Apr 02, 2026	47.17	48.40	46.27	47.58	438.01K
Apr 01, 2026	50.33	51.00	48.64	48.90	675.32K

Contact Details

Waltham, MA 02453

United States

https://www.spyre.com 617 651 5940

About Company

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4�7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4�7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4�7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Spyre Therapeutics, Inc. (NASDAQ:SYRE) closed at $69.13 USD, losing -$0.29 (-0.42%) from the previous close of $69.42. The stock is currently mid-range between its 52-week high and low $12.29 and $76.00. With a market capitalization of about $4.18 billion, Spyre Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.94). Key stats such as the average daily volume over the past year has been around 1.05 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Spyre Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cameron Turtle, the company employs approximately 73 people and listed since April 07, 2016. Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 17.76%, SMA50 26.25%, SMA200 89.11%). The stock’s 14-day RSI is 71.88 (overbought), while the ATR of 2.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.7% below its high and over 295.51% above its low. Average 10-day trading volume of 1.09 million shares is slightly above the 3-month average of 981.11 thousand, indicating heightened recent market interest.

Valuation Metrics

Spyre Therapeutics, Inc. trades at a P/E ratio of -154.36, slightly below the S&P 500 average, with a price-to-sales ratio of 46.21 and a price-to-book ratio of 33.49 reflecting a rich premium to book value. The P/FCF stands at -24.71, also below market averages. Compared to sector medians, Spyre Therapeutics, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Spyre Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.25. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Spyre Therapeutics, Inc. generated EPS of -$2.08 over the past year. Five-year average earnings growth is 44.61%. Wall Street analysts project EPS growth of -19.29% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $106.00 to $43.00. The high target offers 53.33% upside. The low target suggests -37.8% downside. The mean target is $76.40. This offers 10.52% upside. Spyre Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 19, 2026, missed forecasts by 6.06%. The prior quarter beat by -77.94%. Over the last six quarters, Apple has recorded several small beats. These include -99.83% in November 07, 2024.

Shareholding & Insider Activity

Spyre Therapeutics, Inc. has 60.40 million shares outstanding. The public float is 46.75 million shares, elevated short interest at 28.03% of float. This equals 13.19 million shares. The short ratio is 25.91 days. Institutional investors hold 95.32% of the float. Insiders own 8.8%. Turtle Cameron holds 612.54 thousand shares, Burrows Scott L has 97.99 thousand shares and Albers Jeffrey W. has 27.36 thousand shares. Over the past six months, insider transactions show net selling. They sold 39.66 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Spyre Therapeutics has not generated any revenue.
On valuation metrics, Spyre Therapeutics trades at a P/E of -154.36, P/S of 46.21 and P/B of 33.49. The current ratio is 13.25 and quick ratio is 13.25. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -35.91 days , indicating it collects cash faster than it pays suppliers.

Price Forecast & Outlook

Our AI price prediction model suggests that Spyre Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 16.94%, with price expected at $80.84 by May 18, 2026, within a range of $75.95 to $85.58 3-Month Outlook: Projected rise of 178.42%, reaching $192.47 by July 31, 2026, with a range of $190.28 to $198.32. 1-Year Outlook: Projected gain of 6.64%, with price at $73.72 by May 04, 2027, within a range of $69.68 to $77.17.

Key Takeaways

Spyre Therapeutics, Inc. (NASDAQ:SYRE) shares are flat 2.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Spyre Therapeutics, Inc. trading at a premium to the broader market with a P/E of -154.36. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $74.45, suggesting 7.7% upside. Our AI forecast model points to short-term strength (16.94% over two weeks), a medium-term rise (178.42% over three months), and a longer-term gain (6.64% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Spyre Therapeutics, Inc. (SYRE) stock price?

Spyre Therapeutics, Inc. (NASDAQ: SYRE) stock price is $69.13 in the last trading session. During the trading session, SYRE stock reached the peak price of $71.67 while $67.18 was the lowest point it dropped to. The percentage change in SYRE stock occurred in the recent session was -0.42% while the dollar amount for the price change in SYRE stock was - $0.29.

SYRE's industry and sector of operation?

The NASDAQ listed SYRE is part of Biotechnology industry that operates in the broader Healthcare sector. Spyre Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SYRE?

No Data

How SYRE did perform over past 52-week?

SYRE's closing price is 462.72% higher than its 52-week low of $12.29 where as its distance from 52-week high of $76.00 is -9.04%.

How many employees does SYRE have?

Number of SYRE employees currently stands at 73.

Link for SYRE official website?

Official Website of SYRE is: https://www.spyre.com

How do I contact SYRE?

SYRE could be contacted at phone 617 651 5940 and can also be accessed through its website. SYRE operates from 221 Crescent Street, Waltham, MA 02453, United States.

How many shares of SYRE are traded daily?

SYRE stock volume for the day was 991.59K shares. The average number of SYRE shares traded daily for last 3 months was 1.05M.

What is the market cap of SYRE currently?

The market value of SYRE currently stands at $4.18B with its latest stock price at $69.13 and 60.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	73
Beta	2.94
Sales or Revenue	N/A
5Y Sales Change%	-0.974%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

SYRE Company Profile and Key Details

Spyre Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook